All Stories

  1. Phytochemical characterization and anticancer potential of Psidium cattleianum Sabine aerial parts’ n-hexane extract and its subfractions

    Article • PLOS One, October 2025, PLOS

    Hassan Y. Ebrahim, PhD

  2. Safety, Pharmacokinetics, Translational and Molecular Mechanistic Insights on the Prostate Cancer Recurrence Suppressor Pseurotin A

    Article • Molecules, October 2025, MDPI AG

    Hassan Y. Ebrahim, PhD

  3. Synergistic effects of abietic acid combined with doxorubicin on apoptosis induction in a human colorectal cancer cell line

    Article • Scientific Reports, May 2025, Springer Science + Business Media

    Hassan Y. Ebrahim, PhD

  4. (−)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis

    Article • Nutrients, April 2025, MDPI AG

    Hassan Y. Ebrahim, PhD

  5. Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation

    Article • Marine Drugs, March 2023, MDPI AG

    Hassan Y. Ebrahim, PhD

  6. Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice

    Article • Molecules, February 2023, MDPI AG

    Hassan Y. Ebrahim, PhD

  7. Melaleuca rugulosa (Link) Craven Tannins: Appraisal of anti-inflammatory, radical scavenging activities, and molecular modeling studies

    Article • Journal of Ethnopharmacology, November 2022, Elsevier

    Hassan Y. Ebrahim, PhD

  8. Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2

    Article • Cancers, July 2022, MDPI AG

    Hassan Y. Ebrahim, PhD

  9. Ethnopharmacological impact of Melaleuca rugulosa (Link) Craven leaves extract on liver inflammation

    Article • Journal of Ethnopharmacology, June 2022, Elsevier

    Hassan Y. Ebrahim, PhD

  10. The Tobacco β-Cembrenediol: A Prostate Cancer Recurrence Suppressor Lead and Prospective Scaffold via Modulation of Indoleamine 2,3-Dioxygenase and Tryptophan Dioxygenase

    Article • Nutrients, April 2022, MDPI AG

    Hassan Y. Ebrahim, PhD

  11. Growth Inhibition and Apoptotic Effect of Pine Extract and Abietic Acid on MCF-7 Breast Cancer Cells via Alteration of Multiple Gene Expressions Using In Vitro Approach

    Article • Molecules, January 2022, MDPI AG

    Hassan Y. Ebrahim, PhD

  12. Synthesis, anticancer evaluation and molecular docking studies of new heterocycles linked to sulfonamide moiety as novel human topoisomerase types I and II poisons

    Article • Bioorganic Chemistry, May 2020, Elsevier

    Hassan Y. Ebrahim, PhD, Dr walid Ebaied elgammal

  13. Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors

    Article • International Journal of Molecular Sciences, November 2019, MDPI AG

    Hassan Y. Ebrahim, PhD, Dr walid Ebaied elgammal

  14. Prodigiosins from a marine sponge-associated actinomycete attenuate HCl/ethanol-induced gastric lesion via antioxidant and anti-inflammatory mechanisms

    Article • PLOS One, June 2019, PLOS

    Professor Ahmed E Abdel Moneim, Hassan Y. Ebrahim, PhD

  15. Novel liquid-liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (-)-oleocanthal and its oral anti-breast cancer activity

    Article • PLOS One, April 2019, PLOS

    Hassan Y. Ebrahim, PhD, Khalid El Sayed

  16. (−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo

    Article • Nutrients, February 2019, MDPI AG

    Hassan Y. Ebrahim, PhD, Prof Wael Hananeh

  17. 131 -Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo

    Article • Molecular Carcinogenesis, July 2018, Wiley

    Hassan Y. Ebrahim, PhD

  18. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies

    Article • Bioorganic & Medicinal Chemistry, December 2017, Elsevier

    Hassan Y. Ebrahim, PhD

  19. Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies

    Article • Nutrition and Cancer, October 2017, Taylor & Francis

    Hassan Y. Ebrahim, PhD

  20. The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment

    Article • European Journal of Pharmacology, September 2017, Elsevier

    Hassan Y. Ebrahim, PhD

  21. The tobacco cembranoid (1 S ,2 E ,4 S ,7 E ,11 E )-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies

    Article • Bioorganic & Medicinal Chemistry, August 2017, Elsevier

    Hassan Y. Ebrahim, PhD

  22. Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies

    Article • Journal of Natural Products, February 2017, American Chemical Society (ACS)

    Hassan Y. Ebrahim, PhD

  23. (1 S ,2 E ,4 S ,7 E ,11 E )-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies

    Article • Bioorganic & Medicinal Chemistry, November 2016, Elsevier

    Hassan Y. Ebrahim, PhD

  24. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor

    Article • Oncotarget, April 2016, Impact Journals, LLC

    Hassan Y. Ebrahim, PhD

  25. Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds

    Article • Marine Drugs, March 2016, MDPI AG

    Hassan Y. Ebrahim, PhD

  26. Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, andIn VivoInvasive Growth Through Targeting C-Met

    Article • Phytotherapy Research, January 2016, Wiley

    Hassan Y. Ebrahim, PhD

  27. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion

    Article • Bioorganic & Medicinal Chemistry, January 2016, Elsevier

    Hassan Y. Ebrahim, PhD

  28. PEGylated γ-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability

    Article • European Journal of Pharmaceutics and Biopharmaceutics, October 2015, Elsevier

    Hassan Y. Ebrahim, PhD, Assistant Professor Saeed Alqahtani

  29. Endocrine therapy in metastatic breast cancer: a closer look at the current clinical practice

    Article • The Journal of Community and Supportive Oncology, October 2015, Frontline Medical Communications, Inc.

    Hassan Y. Ebrahim, PhD

  30. Inflammatory metastatic breast cancer with gallbladder metastasis: an incidental finding

    Article • The Journal of Community and Supportive Oncology, July 2015, Frontline Medical Communications, Inc.

    Hassan Y. Ebrahim, PhD

  31. Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling

    Article • Marine Drugs, January 2015, MDPI AG

    Hassan Y. Ebrahim, PhD

  32. 3-O-[N-(p-fluorobenzenesulfonyl)-carbamoyl]-oleanolic acid, a semisynthetic analog of oleanolic acid, induces apoptosis in breast cancer cells

    Article • European Journal of Pharmacology, October 2014, Elsevier

    Hassan Y. Ebrahim, PhD

  33. Discovery, Optimization, and Pharmacophore Modeling of Oleanolic Acid and Analogues as Breast Cancer Cell Migration and Invasion Inhibitors Through Targeting Brk/Paxillin/Rac1 Axis

    Article • Chemical Biology & Drug Design, July 2014, Wiley

    Hassan Y. Ebrahim, PhD

  34. The Marine-Derived Sipholenol A-4-O-3′,4′-Dichlorobenzoate Inhibits Breast Cancer Growth and Motility in Vitro and in Vivo through the Suppression of Brk and FAK Signaling

    Article • Marine Drugs, April 2014, MDPI AG

    Hassan Y. Ebrahim, PhD